Posted by Michael Wonder on 29 Jan 2017
Pfizer receives positive CHMP opinion in Europe for Xeljanz (tofacitinib citrate) for the treatment of moderate to severe active rheumatoid arthritis
27 January 2017 - Pfizer announced today that the CHMP of the EMA adopted a positive opinion recommending Xeljanz (tofacitinib citrate) 5 mg twice daily for the treatment of patients with moderate to severe active rheumatoid arthritis.
The CHMP’s opinion will now be sent to the European Commission for final decision. If approved, Xeljanz in combination with methotrexate will be indicated for the treatment of moderate to severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Xeljanz can be given as monotherapy in case of intolerance to methotrexate or when treatment with methotrexate is inappropriate.
